Petersen P B, Husted S, Mortensen A, Andreasen F
Scand J Rheumatol. 1979;8(1):54-6.
Out of a total of 150 patients attending an out-patient clinic for anticoagulant therapy, 12 had disorders which normally would indicate a prolonged use of an antirheumatic drug. To 6 of these patients, naproxen (1/4 g twice daily) was given while anticoagulant treatment with phenprocoumon was continued in an unchanged dosage schedule (average dose 2.1 mg/day). On the average, the prothrombin complex activity (PP%) was reduced to a stable level 10--20% below that obtained during a 2-month period before the naproxen treatment was started. No bleeding episodes or other effects were observed. Thus the simultaneous administration of naproxen caused no problems for the maintenance of a stable anticoagulant therapy.
在总共150名到门诊接受抗凝治疗的患者中，有12名患有通常需要长期使用抗风湿药物的疾病。给其中6名患者服用萘普生（每日两次，每次1/4克），同时继续按照不变的剂量方案使用苯丙香豆素进行抗凝治疗（平均剂量为2.1毫克/天）。平均而言，凝血酶原复合物活性（PP%）降至比开始萘普生治疗前2个月期间所达到的水平低10%至20%的稳定水平。未观察到出血事件或其他影响。因此，同时服用萘普生对维持稳定的抗凝治疗没有造成问题。
